About

This forum is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.

The programmes are free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.

Publications

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Publications

A retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab

Publications

Upadacitinib in psoriatic arthritis with prior TNF-inhibitor failure: a 56-week real-world study

Publications

A retrospective observational study of effectiveness of sequential biologic and targeted synthetic DMARDs in psoriatic arthritis in the UK

Publications

Long‑term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: Treatment persistence is differentially affected by disease phenotype, obesity and sex

Publications

Long-term management of elderly patients with rheumatoid arthritis treated with tocilizumab: comparison of patients over and under 75 years old

Publications

Comparative risk of uveitis with Janus kinase inhibitors versus tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic diseases: A target trial emulation study

Publications

Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis

Publications

Clinical efficacy of JAK inhibitors for rheumatoid arthritis patients with poor-prognosis factors: The ANSWER cohort study

Publications

Real-world data on treatment persistence and measures to minimize cardiovascular risk in rheumatic patients using upadacitinib

Publications

Association of BMI, BMR, BSA, and body weight with psoriasis severity and treatment response: Evidence from a real-world cohort

Publications

Skeletal muscle effects of Janus kinase inhibition in rheumatoid arthritis (RAMUS): a single-arm, experimental medicine study

Publications

Sonelokimab, an IL-17A- and IL-17F- inhibiting nanobody for active psoriatic arthritis: A randomized, placebo-controlled Phase 2 trial

Publications

Real-world sex differences in treatment persistence and reasons for discontinuation in psoriatic arthritis patients: results from the German RABBIT-SpA register

Publications

Clinical efficacy, drug retention and recurrence of ixekizumab across psoriasis severities: A multicenter retrospective analysis of 354 patients

Publications

Risk of adverse events of psoriasis treatment with biologic agents and new small molecules—BIOBADADERM Registry

Publications

Cardiovascular safety of systemic psoriasis treatments: A prospective cohort study in the BIOBADADERM registry

Publications

Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint

Publications

Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): Two phase 3, randomised, placebo-controlled and active-comparator controlled trials

Publications

Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years

Publications

Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: Results through Week 24 of the Phase 3b, randomised, double-blind, placebo-controlled APEX study

Publications

Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS post hoc analysis

Publications

Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study

Publications

A real-world comparison of clinical effectiveness of upadacitinib, tumor necrosis factor inhibitors or interleukin-17 inhibitors in patients with axial spondyloarthritis after switching from an initial tumor necrosis factor inhibitor treatment

Publications

A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: the EARLY study

Publications

Efficacy, safety, and drug survival during the first year of biologic therapy for psoriasis in elderly versus younger patients

Publications

Efficacy and safety of guselkumab subcutaneous induction and maintenance in participants with moderately to severely active Crohn’s disease: Results from the Phase 3 GRAVITI study

Publications

Safety profile of upadacitinib: Descriptive analysis in over 27,000 patient‑years across rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, and inflammatory bowel disease

Publications

Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis

Publications

Real-world effectiveness of tofacitinib on ulcerative colitis-associated spondyloarthropathy: A multicenter prospective study from the Italian group for the study of inflammatory bowel diseases (IG-IBD)

Publications

Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: A pooled analysis of patients from the Phase 3 KEEPsAKE 1 and 2 studies

Publications

Comparative effectiveness and safety of adalimumab, secukinumab, and upadacitinib in psoriatic arthritis: A prospective cohort study based on PARWCH cohort